Affiliation:
1. I.I. Mechnikov North-Western State Medical University, Ministry of Health of Russia
2. JSC “GENERIUM”;
I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia (Sechenov University);
National Research Center – Institute of Immunology Federal Medical-Biological Agency of Russia
Abstract
Knowledge about the mechanisms of action of mesenchymal multipotent stromal cells (MSC) has undergone a significant evolution since their discovery. From the first attempts to use the remarkable properties of MSC in restoring the functions of organs and tissues, the most important question arose – how safe their use would be? One of the aspects of safety of the use of such biomaterial is tumorogenicity and oncogenicity. Numerous studies have shown that the mechanisms by which MSC realize their regenerative potential can, in principle, have a stimulating effect on tumor cells. This review presents specific mechanisms that have a potentially pro-tumor effect, which include the homing of MSC to the tumor site, support for replicative and proliferative signaling of both cancer cells and cancer stem cells, angiogenesis, and effects on the epithelial-mesenchymal transition. Along with pro-tumor mechanisms, the mechanisms of possible antitumor action are also described – direct suppression of tumor growth, loading and transportation of chemotherapeutic agents, oncolytic viruses, genetic modifications for targeting cancer, delivery of “suicide genes” to the tumor. Also, in conclusion, a small review of the current clinical trials of MSC as antitumor agents for malignant neoplasms of various localization (gastrointestinal tract, lungs, ovaries) is given.
Subject
Oncology,Hematology,Pediatrics, Perinatology and Child Health
Reference180 articles.
1. Wang Y., Chen X., Cao W., Shi Y. Plasticity of mesenchymal stem cells in immunomodulation: pathological and therapeutic implications. Nat Immunol 2014;15(11):1009–16. doi: 10.1038/ni.3002.
2. da Silva Meirelles L., Fontes A.M., Covas D.T., Caplan A.I Mechanisms involved in the therapeutic properties of mesenchymal stem cells. Cytokine Growth Factor Rev 2009;20(5–6):419–27. doi: 10.1016/j.cytogfr.2009.10.002.
3. https://clinicaltrials.gov/ct2/results?term=mesenchymal+stem+cell&Search=Apply&recrs=b&recrs=a&recrs=f&recrs=d&recrs=e&age_v=&gndr=&type=&rslt=&phase=2&phase=3 (Date of access – 02.03.2021).
4. Phinney D.G., Galipeau J., Krampera M., Martin I., Shi Y., Sensebe L. MSCs: science and trials. Nat Med 2013;19(7):812. doi: 10.1038/nm.3220.
5. Elzaouk L., Moelling K., Pavlovic J. Anti-tumor activity of mesenchymal stem cells producing IL-12 in a mouse melanoma model. Exp Dermatol 2006;15(11):865–74. doi: 10.1111/j.1600-0625.2006.00479.x.
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献